(Q38125007)

29 August 2017

0 references

Addition of antimuscarinics to alpha-blockers for treatment of lower urinary tract symptoms in men: a meta-analysis (English)

1 reference

29 August 2017

1 reference

Zhixiang Xin

1

1 reference

29 August 2017

Yiran Huang

2

1 reference

29 August 2017

Jun Lu

3

1 reference

29 August 2017

Qi Zhang

4

1 reference

29 August 2017

Chen Chen

5

1 reference

29 August 2017

language of work or name

English

0 references

publication date

1 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

82

1 reference

29 August 2017

2

1 reference

29 August 2017

270-277

1 reference

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society

29 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Prevalence of lower urinary tract symptoms in men aged 45-79 years: a population-based study of 40 000 Swedish men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey"

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Impact of lower urinary tract symptoms on quality of life using Functional Assessment Cancer Therapy scale.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Antimuscarinic therapy in men with lower urinary tract symptoms: what is the evidence?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: A systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Safety of anticholinergics in patients with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Combination antimuscarinics and alpha-blockers for benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Low-Dose Anticholinergic Combination Therapy in Male Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Randomized Controlled Trial to Treat Benign Prostatic Hyperplasia with Overactive Bladder Using an Alpha-blocker Combined with Anticholinergics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Lower urinary tract symptoms associated with benign prostatic hyperplasia: combined treatment with fesoterodine fumarate extended-release and tamsulosin--a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Antimuscarinic mechanisms and the overactive detrusor: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

Overactive bladder: improving the efficacy of anticholinergics by dose escalation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.04.045

10.1016/J.UROLOGY.2013.04.045

7 January 2021

Identifiers

DOI

1 reference

29 August 2017

1 reference